cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Terns Pharmaceuticals Inc
4 own
5 watching
Current Price
$7.91
$-0.14
(-1.74%)
logo-tern
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
297.53M
52-Week High
52-Week High
10.67
52-Week Low
52-Week Low
1.45
Average Volume
Average Volume
0.11M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization297.53M
icon52-Week High10.67
icon52-Week Low1.45
iconAverage Volume0.11M
iconDividend Yield--
iconP/E Ratio--
What does the Terns Pharmaceuticals Inc do?
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Read More
How much money does Terns Pharmaceuticals Inc make?
News & Events about Terns Pharmaceuticals Inc.
Globe Newswire
1month ago
FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic ...
Globe Newswire
1month ago
FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic ...
Ticker Report
1month ago
Terns Pharmaceuticals, Inc. (NASDAQ:TERN Get Rating) major shareholder Biosciences Fund V. L.P. Lav sold 1,500,000 shares of the firms stock in a transaction dated Wednesday, November 23rd. The shares were sold at an average price of $5.50, for a total value of $8,250,000.00. ...
Globe Newswire
2 months ago
Data demonstrated treatment with TERN-501 resulted in time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker linked to NASH histologic efficacy Phase 2a DUET trial evaluating TERN-501 alone and in combination with TERN-101, the first trial assessing both THR- and FXR...
Ticker Report
4 months ago
Terns Pharmaceuticals, Inc. (NASDAQ:TERN Get Rating) major shareholder Vivo Opportunity, Llc bought 600,000 shares of the companys stock in a transaction that occurred on Wednesday, September 7th. The stock was bought at an average price of $3.60 per share, with a total value of $2,...
Frequently Asked Questions
Frequently Asked Questions
What is Terns Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Terns Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Terns Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Terns Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Terns Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Terns Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Terns Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Terns Pharmaceuticals Inc?
plus_minus_icon
What percentage is Terns Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Terns Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$7.91
$-0.14
(-1.74%)
logo-tern
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00